



# When should a rare inherited connective tissue disorder be suspected in bicuspid aortic valve by primary-care internists and cardiologists? Proposal of a score

Guglielmina Pepe<sup>1,2,3</sup> · Betti Giusti<sup>1,3,4</sup> · Stefania Colonna<sup>5</sup> · Maria Pia Fugazzaro<sup>6</sup> · Elena Sticchi<sup>1,3,4</sup> · Rosina De Caro<sup>1,3,4</sup> · Ada Kura<sup>1,3,4</sup> · Elisa Pratelli<sup>7</sup> · Daniela Melchiorre<sup>8</sup> · Stefano Nistri<sup>6</sup>

Received: 30 April 2020 / Accepted: 21 July 2020

© The Author(s) 2020

## Abstract

Size threshold for aortic surgery in bicuspid aortic valve (BAV) is debated. Connective tissue disorders (CTDs) are claimed as a clinical turning point, suggesting early surgery in BAV patients with CTD. Thus, we aimed at developing a score to detect high risk of carrying CTDs in consecutive BAVs from primary care. Ninety-eight BAVs without ectopia lentis or personal/family history of aortic dissection were studied at the Marfan syndrome Tuscany Referral Center. Findings were compared with those detected in 84 Marfan patients matched for sex and age. We selected traits with high statistical difference between MFS and BAV easily obtainable by cardiologists and primary-care internists: mitral valve prolapse, myopia  $\geq 3$ DO, pectus carinatum, pes planus, wrist and thumb signs, and difference between aortic size at root and ascending aorta  $\geq 4$  mm. Clustering of  $\geq 3$  of these manifestations were more frequent in Marfan patients than in BAVs (71.4% vs 6.1%,  $p < 0.0001$ ) resulting into an Odds Ratio to be affected by MFS of 38.3 (95% confidence intervals 14.8–99.3,  $p < 0.0001$ ). We propose a score assembling simple clinical and echocardiographic variables resulting in an appropriate referral pattern of BAVs from a primary-care setting to a tertiary center to evaluate the presence of a potential, major CTD.

**Keywords** Aortopathy · Congenital heart disease · Connective tissue disorders · Bicuspid aortic valve · Marfan syndrome · Primary care

✉ Guglielmina Pepe  
guglielmina.pepe@unifi.it

<sup>1</sup> Marfan Syndrome and Related Disorders Regional Referral Center, Careggi Hospital, Viale Gaetano Pieraccini, 50139 Florence, Italy

<sup>2</sup> Research and Innovation Center for Marfan Syndrome and Related Disorders, Careggi Hospital, Florence, Italy

<sup>3</sup> Department of Experimental and Clinical Medicine, Section of Critical Medical Care and Medical Specialities, University of Florence, Florence, Italy

<sup>4</sup> Atherothrombotic Diseases Tuscany Referral Center, Careggi Hospital, Florence, Italy

<sup>5</sup> Outpatient Cardiology Unit, Health District 1 ULSS 6, Vigonza and Carmignano di Brenta, Padua, Italy

<sup>6</sup> Cardiology Service, CMSR Veneto Medica, Altavilla Vicentina, Italy

<sup>7</sup> Specialization in Physical and Rehabilitation Medicine, Recovery and Rehabilitation Agency, Careggi Hospital, Florence, Italy

<sup>8</sup> Department of Experimental and Clinical Medicine, Section of Rheumatology, University of Florence, Florence, Italy

## Introduction

Bicuspid aortic valve (BAV) is the most common congenital heart disease with a prevalence of 1–2% [1–3]. As such, BAV may be commonly evaluated by general practitioner in primary care, as well as internist in multiple settings. It is frequently associated to thoracic aortic aneurysm (TAA) [4–6]. Early studies on BAV reported structural abnormalities of thoracic aortic tissue resembling those detected in Marfan syndrome (MFS) [7]. More recently, a higher percentage of BAV has been reported in Marfan (MF) patients with respect to general population [8, 9], suggesting common pathogenetic mechanisms at least in some patients [3, 9]. Moreover, an absolute increased risk of aortic dissection (AD) has been reported in BAV patients [10, 11]. These issues lead to aggressive recommendations for elective aortic surgery for BAVs similar to those adopted in MF patients. Subsequently, however, long-term independent studies [12–14] produced evidences supporting new guidelines providing separate threshold for aortic surgery in MF and

BAV patients [12–14]. Indeed, a recent meta-analysis [15] indicates a low risk of rupture or dissection of moderately dilated aortas without evidence that those related to BAV perform more poorly than others. These data further support the recommended threshold of 55 mm for intervention in BAVs without risk factors [12–14]. Nonetheless, there is still dispute on this topic with some suggesting more aggressive surgical approach in BAV patients and others expanding the risk factors to specific phenotypes (i.e. the root phenotype [5, 16]).

Reported clinical and genetic overlaps between MFS and BAV [3, 9, 17] suggesting that early detection of syndromic connective tissue disorders (CTDs), underlying aortic ectasia in BAVs, might be useful to address patients to distinct decision-making algorithms towards aortic surgery [17]. However, direct referring of each BAV patient with TAA for a clinico-genetic assessment looks largely unpractical and unsustainable, since BAV is prevalent and commonly associated to significant aortic dilatation.

Thus, we aimed at searching for an easily applicable clinical score supporting clinical cardiologists, general practitioners and internists to detect those BAVs with a high risk of significant CTDs, prompting their appropriate referral to a tertiary center for clinico-genetic assessment.

## Materials and methods

### Patients

Ninety-eight patients with BAV without ectopia lentis or personal/family history of AD and CTDs (i.e. Marfan syndrome, Loeys-Dietz syndromes, vascular Ehlers-Danlos) were consecutively referred by cardiologists of primary-care facilities to the MF Tuscany Referral Center for being evaluated by one clinical geneticist to investigate the presence of MFS or other syndromic CTDs [18]. According to Ghent2 criteria for the diagnosis of Marfan syndrome [19], most of patients with BAV presented neither two clinical signs nor a clinical and a genetic one. The 60/98 BAV patients which accepted to undergo FBN1 mutation analysis turned out do not carry any FBN1 mutation.

Eighty-four MF patients, diagnosed by new Ghent criteria [18, 19], similar for sex and age, were extracted from the clinical database of the Center for comparison.

### Transthoracic echocardiography

Aortic size was assessed by 2D transthoracic echocardiography by leading edge-to-leading edge method in parasternal long-axis views, at end-diastole [8, 20]. Bicuspid valves are classified as type 1 (right–left coronary cusp fusion), type 2 (right-non-coronary cusp fusion), and type 3

(left-non-coronary cusp fusion). To take into account phenotypic differences of aortic dilatation in BAV and MF patients [6, 20], we analyzed the difference between aortic size at Valsalva sinuses and at proximal ascending aorta (aortic root (AR)—ascending aorta (AA) diameters =  $\Delta\text{AR-AA}$ ) and we categorized patients on the basis of a threshold value of 4 mm derived from 98 control subjects without family history of either BAV or MFS comparable for age and sex.

### Systemic features of Marfan syndrome

Systemic features (SF) collected and reported in Table 1 were assessed by the Senior investigator (GP).

### Informed written consent

All patients gave informed written consent to participate in the study approved by the ethic committee.

### Statistical analysis

The results were expressed as median and range or interquartile range (IQR) for continuous variables or percentages for categorical variables. Medians were compared by Mann–Whitney test, and categorical variables were analysed by the chi-square test using SPSS package v19 (SPSS Inc., Chicago, IL, USA). Statistical significance was accepted at  $p$  value  $< 0.05$ .

## Results

### Demographic, echocardiographic and clinical characteristics of MF and BAV patients

Demographic, echocardiographic and clinical characteristics of MF and BAV patients are reported in Table 1. BAV patients had type 1 morphology in 77/98 (78.6%), type 2 morphology in 20/98 (20.4%) and type 3 in 1/98 (1.0%) and were associated to moderate or severe aortic regurgitation in 29/98 patients (29.6%), moderate or severe aortic stenosis in 7/98 patients (7.1%), and moderate or severe calcification in 6/98 patients (6.1%). MF patients were taller, had larger aortic size at aortic root, while smaller ascending aorta, resulting in a significantly higher  $\Delta\text{AR-AA}$  9.0 (6.0–12.0) vs  $-0.6$  ( $-5.9$  to 3.0) mm, respectively,  $p < 0.0001$  (Fig. 1).

Indeed, only 19.4% of BAV patients had  $\Delta\text{AR-AA}$  exceeding the value of 4 mm, while 91.7% of MFs satisfied this criterion (Table 1). Among all clinical traits, we selected those with high statistical difference between MFS and BAV (in bold in Table 1) and readily obtainable by cardiologists in a non-referral setting, to develop a score to detect BAVs at high risk of carrying CTDs: mitral valve

**Table 1** Demographic and clinical characteristics of the studied BAV and MFS patients

	FBN1	BAV <i>N</i> =98	MFS <i>N</i> =84	<i>P</i> value BAV vs MFS
Age, years		42 (18–72)	43 (18–69)	0.109
Sex Male, <i>n</i> (%)		70 (71.4)	65 (77.4)	0.360
Height, cm		176 (150–194)	183 (149–205)	<0.0001
Weight, kg		74 (46–112)	75 (33–115)	0.540
Aortic root diameter, mm		37.5 (26–53)	42.0 (29–56)	<0.0001
Ascending aortic diameter, mm		38.0 (22–53)	32.0 (24–60)	0.002
$\Delta$ AR-AA, mm (IQR)		−0.6 (−5.9–3.0)	9.0 (6.0–12.0)	<0.0001
<b><math>\Delta</math>AR-AA &gt; 5 mm, <i>n</i> (%)</b>		19 (19.4)	77 (91.7)	<0.0001
Systemic features (SF)				
<b>Mitral valve prolapse*</b> (MVP), <i>n</i> (%)		28 (28.6)	62 (73.8)	<0.0001
Dolicocephaly: face and/or neck, <i>n</i> (%)		72 (73.4)	48 (57.1)	0.020
Jaw ipo and/or retrognathic, <i>n</i> (%)		76 (77.6)	40 (47.6)	<0.0001
<b>Pectus carinatum deformity*</b> , <i>n</i> (%)		20 (20.4)	36 (42.9)	0.001
Pectus excavatum, <i>n</i> (%)		31 (31.6)	35 (41.7)	0.160
Kyphosis, <i>n</i> (%)		30 (30.6)	18 (21.4)	0.161
Scoliosis > 20°, <i>n</i> (%)		10 (10.2)	41 (48.8)	<0.0001
Reduced elbow extension, <i>n</i> (%)		17 (17.3)	30 (35.7)	0.005
<b>Wrist and thumb sign†</b> , <i>n</i> (%)		3 (3.1)	23 (27.4)	<0.0001
<b>Plain pes planus</b> , <i>n</i> (%)		12 (12.2)	41 (48.8)	<0.0001
Hindfoot deformities <i>n</i> (%)		33 (33.6)	31 (36.9)	0.649
<b>Myopia &gt; 3 diopters</b> , <i>n</i> (%)		14 (14.3)	32 (38.1)	0.0002
Pneumothorax, <i>n</i> (%)		3 (3.1)	7 (8.3)	0.119
Striae, <i>n</i> (%)		82 (83.7)	69 (82.1)	0.789

BAV bicuspid aortic valve; patients were all assessed according to Ghent-2 criteria (19), MFS Marfan syndrome,  $\Delta$ AR-AA Delta Aortic Root—Ascending Aorta diameter, \* of any kind, † thumb sign is positive when the entire nail of the thumb projects beyond the ulnar border of the hand which is clenched without any assistance, the wrist sign is positive when the thumb overlaps the terminal phalanx of the fifth digit when it grasps the contra-lateral wrist. \*\*FBN1 gene analysis was performed in 60/98 BAV patients, all the ones which accepted to undergo mutation analysis. All patients (100%) turned out to be negative for FBN1 mutations. Among the other 38 patients, 19 had an aorta diameter with z-score < 2, 3 did not have aortic root ectasia, the remaining 16 had a systemic features' score between 0 and 3 (11 patients), 4 and 5 (the remaining 5). Furthermore, these last patients did not have mitral valve prolapse or marfanoid aspect. Family history was negative for MFS (data not shown). The results were expressed as median and range or interquartile range (IQR) for continuous variables or percentages for categorical variables. Medians were compared by Mann–Whitney test and categorical variables were analysed by the chi-square test by SPSS package v19 (SPSS Inc., Chicago, IL, USA)

prolapse, myopia  $\geq 3$ DO, pectus carinatum, pes planus, wrist and thumb signs, and  $\Delta$ AR-AA  $\geq 4$  mm.


Patients with 3 or more of these manifestations were *n* = 60 (71.4%) among MFs and *n* = 6 (6.1%) among BAVs (*p* < 0.0001). These 6 BAV patients were similar regarding age, sex and prevalence of moderate-to-severe aortic regurgitation and stenosis to BAVs with < 3 manifestations (data not shown), had smaller aortic size at the aortic root [32.0 (28.0–40.0) mm, vs. 38.3 (25.6–53.0) mm, respectively, *p* = 0.018] and at proximal ascending aorta [31.0 (25.0–37.0) mm vs. 38.5 (22.0–53.0) mm, respectively, *p* = 0.006].  $\Delta$ AR-AA was comparable between BAV patients with  $\geq 3$  [2.0 (− 2.1 to 4.7) mm] to the remaining BAVs [− 1.0 (− 6.0 to 3.0) mm, *p* = 0.257]; moreover, prevalence

of BAV patients with  $\Delta$ AR-AA > 4 mm was not different between the two groups [*n* = 2 (33.3%) vs *n* = 17 (18.5%), respectively, *p* = 0.373]. At logistic regression analysis, subjects with  $\geq 3$  of the six manifestations showed an Odds Ratio to be affected by MFS of 38.3 (95% confidence intervals 14.8–99.3), *p* < 0.0001.

## Discussion

The issue of size threshold for aortic surgery in BAV is still debated [22, 23], though more recent guidelines lean towards a more conservative approach in BAV patients with isolated TAA [12–14]. Indeed, an important agreement has

**Fig. 1** Individual aortic Size at Aortic Root and Ascending Aorta in BAV (left) and MFS (right) patients. BAV patients display a larger ascending aorta diameter respect to root diameter, while the root diameter appears mostly larger in Marfan patients which have also larger aortic size. Aorta in BAV displays a larger ascending vs root aorta diameter. Root diameter and aortic size are larger in MF patients. These data result in a significantly higher  $\Delta$ AR-AA in MF patients respect to BAV patients ( $p < 0.0001$ )



been recently reached to indicate surgical repair when the aortic diameter is  $\geq 5.5$  cm in BAV patients without risk factor (i.e.: family history of aortic dissection or rapid increase in aortic size) or elastopathy, while a lower threshold was maintained for patients with Marfan syndrome”.

The presence of CTD has been suggested as a clinical turning point in this scenario, supporting more conservative attitude in BAV patients without CTD [17]. However, the idea of referring each and every BAV patient with TAA [24] to a tertiary Center is clearly non-realistic due to the prevalence of BAV itself and of BAV-related aortic dilatation [10]. Thus, we studied outpatients with BAV without ectopia lentis or family history of aortic dissection and CTDs (i.e.: clinical conditions supporting per se the need of a clinic-genetic evaluation), consecutively detected in primary care, aiming at identifying signs whose presence strongly suggests the prevalence of CTD. We demonstrate that the combination of three or more characteristics (among those included in our score) (Table 2) identify a very limited number of BAV individuals at real potential risk of CTD, thus deserving an appropriate referral to a tertiary Center specialized in CTDs. This score is specific for Marfan patients but it is not designed to exclude LDS or vEDS patients.

The herein proposed score is based on the combination of systemic traits (myopia  $> 3$  dioptries, pectus carinatum, pes planus, wrist and thumb sign) easily detectable by clinical cardiologists and primary-care internists working in non-referral facility, and echocardiographic characteristics (mitral valve prolapse and  $\Delta$ AR-AA). This score provides a tool to avoid an inappropriate, systematic referral of all BAVs with TAA to a tertiary center for a clinic-genetic assessment with consequent significant reduction of health-care costs and patients’ discomfort.

Von Kodolitsch et al. set up a pre-test probability score of Marfan syndrome in a study population characterized by a

**Table 2** Scoring system for detecting Marfan syndrome among BAV patients


Score	No	Yes
Mitral valve prolapse		
Myopia $\geq 3$ DO		
Pectus carinatum		
Pes planus		
Wrist and thumb signs		
$\Delta$ AR-AA $\geq 4$ mm		
Total score*		

The opportunity to refer the patient at a tertiary Center for MFS evaluation should be considered with a score  $\geq 3$

\*Each feature corresponds to a score of 1. Patients with a total score  $\geq 3$  have an Odds Ratio to be affected by MFS of 38.3 (95% CI 14.8–99.3)

high rate of positive family history and aortic complications requiring surgery (25). Although our findings display some overlapping features, our score cannot be compared to the previous score since the goal of our work required the choice of different manifestations. In fact, our aim prompted us to select features both with highest differences between BAV and MF patients and easily applicable by internists or clinical cardiologists, usually dealing with the majority of BAVs in a non-referral setting.

There are evidences that the so-called root phenotype [26] might represent a more severe form of aortopathy, as recently reviewed [6]. The root phenotype has been found associated with acute aortic events after isolated aortic valve replacement as well as with potentially aortopathy-related genetic variants [9, 27, 28]. Consistently, the root phenotype has been recently included among the adjunctive risk factors to consider when indicating earlier elective surgery for BAV aortopathy [29]. Considering this background, we



**Fig. 2** Schematic representation of the echocardiographic evaluation of the aortic root for patients with either Marfan syndrome or bicuspid aortic valve. Aortic size was measured at Valsalva sinuses (AR) and proximal ascending aorta (AA) (dotted, double headed, arrows). Median aortic diameter at each site are linked by a red straight line, with shaded areas addressing interquartile ranges.  $\Delta AR-AA$ : difference of the aortic size at Valsalva sinuses and at proximal ascending aorta

introduced  $\Delta AR-AA$ , (Fig. 2), trying to resume the different patterns of aortic dilatation observed in BAV and MF patients [6, 20]. This is consistent with the notion that dilatation of the aortic root is less prevalent in BAV, while it is a recognized pattern in MFS, suggesting different anatomic sites of aortic vulnerability [20]. Noteworthy, the six BAV patients with three or more characteristics suggesting significant CTD, were not distinguishable from the other BAVs based on either aortic valve hemodynamic, aortic size or aortic phenotype (assessed as  $\Delta AR-AA$ , as a continuous variable or dichotomized at 4 mm). The clinical implication of this finding is that CTD cannot be either suspected or ruled out simply based on BAV-related aortic phenotypes. Apparent discrepancies between our findings and those supporting the peculiarities of the root-phenotype [22, 26, 27] should be seen cautiously, considering differences of clinical settings possibly resulting into relevant differences among study populations. Our study group was detected in a primary-care setting, while the other studies [22, 26, 27] were performed in patients referred to cardiac surgery centers for either evaluation or intervention. Thus, we believe that this apparent mismatch should be interpreted as an expression of the wide spectrum of BAV syndrome [9, 10, 30, 31]. This is of particular importance in this moment in which several new parameters of risk stratification have been proposed (i.e.: aortic shape, valve morphotypes and aortic phenotype, fluid-dynamics-related risk markers, circulating biomarkers) whose connection with the risk of acute complications in

BAV patients, however, has not been definitely demonstrated [6].

We acknowledge that this study has multiple limitations. We do not have a validation cohort, or we have performed a clinical follow-up of these patients. However, it has been clearly demonstrated that very long follow-up periods in large unselected populations are needed to detect a significant number of aortic events, including surgery and dissection [12, 29]. Thus, we cannot infer that a low estimated score in BAVs without other risk factors [12–14] might favorably influence the shared decision-making process for delayed thoracic aortic intervention (i.e.: at  $\geq 55$  mm), though we show that it can affect the decision not to refer a patient to a tertiary CTD Center. Prognostic implications of our proposed score, should be of course assessed in larger study groups with appropriate follow-up. However, considering aims of the present observational study, we do not feel that these limitations flaw our findings.

In conclusion, we demonstrate that a simple, though accurate clinical and echocardiographic evaluation, when assembled in a score, results in more appropriate referral pattern of BAV outpatients studied in a primary-care setting to tertiary CTD centers. This finding suggests that internists and clinical cardiologists should further refine their clinical skills in evaluating BAVs, adding to a proper family and personal history taking [12–14], the search of systemic traits and peculiar echocardiographic findings which, when present in combination, strongly support the need of a clinic–genetic evaluation for a potential, major CTD.

**Funding** Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Human and animal rights** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** All patients gave informed written consent to participate in the study approved by the Careggi Hospital ethic committee.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Nistri S, Basso C, Marzari C, Mormino P, Thiene G (2005) Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. *Am J Cardiol* 96:718–721
- Verma S, Siu SC (2014) Aortic dilatation in patients with bicuspid aortic valve. *N Engl J Med* 370:1920–1929
- Giusti B, Sticchi E, De Cario R, Magi A, Nistri S, Pepe G (2017) Genetic bases of bicuspid aortic valve: the contribution of traditional and high-throughput sequencing approaches on research and diagnosis. *Front Physiol*. <https://doi.org/10.3389/fphys.2017.00612>
- Nistri S, Sorbo MD, Basso C, Thiene G (2002) Bicuspid aortic valve: abnormal aortic elastic properties. *J Heart Valve Dis* 11:379–373 **Discussion: 373-374**
- Cecconi M, Nistri S, Quarti A, Manfrin M, Colonna PL, Molini E, Perna GP (2006) Aortic dilatation in patients with bicuspid aortic valve. *J Cardiovasc Med (Hagerstown)* 7:11–20
- Della Corte A, Michelena HI, Citarella A, Votta E, Piatti F, Lo Presti F, Ashurov R, Cipollaro M, Forte A (2019) Risk stratification in bicuspid aortic valve aortopathy: emerging evidence and future perspectives. *Curr Probl Cardiol*. <https://doi.org/10.1016/j.cpcardiol.2019.06.002>
- Yassine NM, Shahram JT, Body SC (2017) Pathogenic mechanisms of bicuspid aortic valve aortopathy. *Front Physiol*. <https://doi.org/10.3389/fphys.2017.00687>
- Nistri S, Porciani MC, Attanasio M, Abbate R, Gensini GF, Pepe G (2012) Association of Marfan syndrome and bicuspid aortic valve: frequency and outcome. *Int J Cardiol* 155:324–325
- Pepe G, Nistri S, Giusti B, Sticchi E, Attanasio M, Porciani C, Abbate R, Bonow RO, Yacoub M, Gensini GF (2014) Identification of fibrillin 1 gene mutations in patients with bicuspid aortic valve (BAV) without Marfan syndrome. *BMC Med Genet* 15:23–29
- Michelena HI, Prakash SK, Corte AD, Bissell MM, Anavekar N, Mathieu P, Bossé Y, Limongelli G, Bossone E, Benson DW, Lancellotti P, Isselbacher EM, Enriquez-Sarano M, Sundt TM 3rd, Pibarot P, Evangelista A, Milewicz DM, Body SC, BAVCon Investigators (2014) Bicuspid aortic valve identifying knowledge gaps and rising to the challenge from the international bicuspid aortic valve consortium (BAVCON). *Circulation* 129:2691–2704
- Mordi I, Tzemos N (2012) Bicuspid aortic valve disease: a comprehensive review. *Cardiol Res Pract*. <https://doi.org/10.1155/2012/196037>
- Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb GD, Siu SC (2008) Outcomes in adults with bicuspid aortic valves. *JAMA* 300:1317–1325
- Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, Eidem B, Edwards WD, Sundt TM 3rd, Enriquez-Sarano M (2011) Incidence of aortic complications in patients with bicuspid aortic valves. *JAMA* 306:1104–1112
- Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA (2002) Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg* 73:17–27
- Guo MH, Appoo JJ, Saczkowski R, Smith HN, Ouzounian M, Gregory AJ, Herget EJ, Boodhwani M (2018) Association of mortality and acute aortic events with ascending aortic aneurysm: a systematic review and meta-analysis. *JAMA Netw Open*. <https://doi.org/10.1001/jamanetworkopen.2018.1281>
- Borger MA, Fedak PWM, Stephens EH, Gleason TG, Girdauskas E, Ikonomidis JS, Khoynzhad A, Siu SC, Verma S, Hope MD, Cameron DE, Hammer DF, Coselli JS, Moon MR, Sundt TM, Barker AJ, Markl M, Della Corte A, Michelena HI, Elefteriades JA (2018) The American association for thoracic surgery consensus guidelines on bicuspid aortic valve-related aortopathy: full online-only version. *J Thorac Cardiovasc Surg*. <https://doi.org/10.1016/j.jtcvs.2018.02.115>
- Kallenbach K, Sundt TM, Marwick TH (2013) Aortic surgery for ascending aortic aneurysms under 5.0 cm in diameter in the presence of bicuspid aortic valve. *JACC Cardiovasc Imaging* 6:1321–1326
- Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devreux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010) The revised ghent nosology for the Marfan syndrome. *J Med Genet* 47:476–485
- von Kodolitsch Y, De Backer J, Schüler H, Bannas P, Behzadi C, Bernhardt AM, Hillebrand M, Fuisting B, Sheikhzadeh S, Rybczynski M, Kölbel T, Püschel K, Blankenberg S, Robinson PN (2015) *Appl Clin Genet* 16(8):137–155. <https://doi.org/10.2147/TACG.S60472>
- Nistri S, Grande-Allen J, Noale M, Basso C, Siviero P, Maggi S, Crepaldi G, Thiene G (2008) Aortic elasticity and size in bicuspid aortic valve syndrome. *Eur Heart J* 29:472–479
- Detaint D, Michelena HI, Nkomo VT, Vahanian A, Jondeau G, Sarano ME (2014) Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. *Heart* 100:126–134
- Saeyeldin A, Zafar MA, Li Y, Tanweer M, Abdelbaky M, Gryaznov A, Brownstein AJ, Velasquez CA, Buntin J, Thombre K, Ma WG, Erben Y, Rizzo JA, Ziganshin BA, Elefteriades JA (2019) Decision-making algorithm for ascending aortic aneurysm: effectiveness in clinical application? *J Thorac Cardiovasc Surg* 157:1733–1745
- Sundt TMJ (2019) "Silent killer" or victim of mistaken identity? *Thorac Cardiovasc Surg*. <https://doi.org/10.1016/j.jtcvs.2018.12.010>
- Hiratzka LF, Creager MA, Isselbacher EM, Svensson LG, Nishimura RA, Bonow RO, Guyton RA, Sundt TM 3rd (2016) Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American college of cardiology/American heart association task force on clinical practice guidelines. *JACC* 67:724–731
- Sheikhzadeh S, Kusch ML, Rybczynski M, Kade C, Keyser B, Bernhardt AM, Hillebrand M, Mir TS, Fuisting B, Robinson PN, Berger J, Lorenzen V, Schmidtke J, Blankenberg S, von Kodolitsch Y (2012) A simple clinical model to estimate the probability of Marfan syndrome. *QJM* 105:527–535
- Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, Scognamiglio G, De Feo DVM (2013) Pattern of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve. *JACC Cardiovasc Imaging* 6:1301–1310
- Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T (2012) Risk of late aortic events after an isolated aortic valve replacement for bicuspid aortic valve stenosis with concomitant ascending aortic dilation. *Eur J Cardiothorac Surg* 42:832–837
- Girdauskas E, Geist L, Disha K, Kazakbaev Groß T, Schulz S, Ungelenk M, Kuntze T, Reichenspurner H, Kurth I (2017) Genetic abnormalities in bicuspid aortic valve root phenotype: preliminary results. *Eur J Cardiothorac Surg* 52:156–162

29. Borger MA, Fedak PWM, Stephens EH, Gleason TG, Giridaskas E, Ikonomidis JS, Khojnejhad A, Siu SC, Verma S, Hope MD, Cameron DE, Hammer DF, Coselli JS, Moon MR, Sundt TM, Barker AJ, Markl M, Della Corte A, Michelena HI, Eleftheriades JA (2018) The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve-related aortopathy: full online-only version *J Thorac Cardiovasc Surg* <https://doi.org/10.1016/j.jtcvs.2018.02.115>
30. De Carlo R, Sticchi E, Giusti B, Abbate R, Gensini GF, Nistri S, Pepe G (2014) Bicuspid aortic valve syndrome and fibrillinopathies: potential impact on clinical approach. *International Cardiovascular Forum (ICF)* 1:163–202
31. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, Eidem B, Edwards WD, Sundt TM 3rd, Enriquez-Sarano M (2011) Incidence of aortic complications in patients with bicuspid aortic valves. *JAM* 306:1104–1112

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.